全文获取类型
收费全文 | 20559篇 |
免费 | 2082篇 |
国内免费 | 399篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 356篇 |
妇产科学 | 215篇 |
基础医学 | 2207篇 |
口腔科学 | 430篇 |
临床医学 | 2629篇 |
内科学 | 2630篇 |
皮肤病学 | 154篇 |
神经病学 | 1753篇 |
特种医学 | 1470篇 |
外国民族医学 | 4篇 |
外科学 | 1757篇 |
综合类 | 2431篇 |
一般理论 | 2篇 |
预防医学 | 2072篇 |
眼科学 | 426篇 |
药学 | 2387篇 |
34篇 | |
中国医学 | 1008篇 |
肿瘤学 | 884篇 |
出版年
2023年 | 352篇 |
2022年 | 411篇 |
2021年 | 816篇 |
2020年 | 937篇 |
2019年 | 841篇 |
2018年 | 877篇 |
2017年 | 886篇 |
2016年 | 739篇 |
2015年 | 801篇 |
2014年 | 1473篇 |
2013年 | 1439篇 |
2012年 | 1236篇 |
2011年 | 1345篇 |
2010年 | 1149篇 |
2009年 | 972篇 |
2008年 | 939篇 |
2007年 | 947篇 |
2006年 | 896篇 |
2005年 | 681篇 |
2004年 | 617篇 |
2003年 | 542篇 |
2002年 | 483篇 |
2001年 | 322篇 |
2000年 | 290篇 |
1999年 | 273篇 |
1998年 | 217篇 |
1997年 | 184篇 |
1996年 | 169篇 |
1995年 | 176篇 |
1994年 | 182篇 |
1993年 | 135篇 |
1992年 | 141篇 |
1991年 | 139篇 |
1990年 | 146篇 |
1989年 | 133篇 |
1988年 | 122篇 |
1987年 | 99篇 |
1986年 | 95篇 |
1985年 | 120篇 |
1984年 | 113篇 |
1983年 | 99篇 |
1982年 | 86篇 |
1981年 | 95篇 |
1980年 | 79篇 |
1979年 | 48篇 |
1978年 | 35篇 |
1977年 | 31篇 |
1976年 | 35篇 |
1975年 | 18篇 |
1973年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献
3.
目的探讨急性主动脉夹层患者首发症状与院前延迟的关系,为临床实施院前针对性健康教育提供参考。方法选取急性主动脉夹层患者488例,收集患者首发症状、一般资料、疾病相关因素、院前相关因素及院前时间,分析首发症状与院前延迟的关系。结果患者院前时间为135.5(48.3, 1 735.5) min,其中院前时间≤150 min 253例(51.8%),>150 min(即院前延迟)235例(48.2%);首发症状多为胸背痛[146例(29.9%)],其次为胸前痛124例(25.4%)、腹痛121例(24.8%)。Logistic回归分析发现自觉病情严重程度、胸背痛是院前延迟的保护因素(P<0.01),腹痛、四肢麻木/疼痛是急性主动脉夹层患者院前延迟的危险因素(P<0.05,P<0.01)。结论急性主动脉夹层患者常以胸背痛为首发症状,腹痛与四肢麻木/疼痛非典型症状是导致急性主动脉夹层患者出现院前延迟的主要因素。需对公众加强疾病相关知识的健康教育,早期采取正确的应对方式,积极就医,缩短院前时间。 相似文献
4.
5.
《International journal of oral and maxillofacial surgery》2022,51(9):1115-1122
The aim of this study was to compare the effectiveness of Harmonic Focus+ scissors with the conventional surgical method regarding surgical blood loss and transfusion of blood products in the surgical treatment of head and neck tumours. In a retrospective study, the intraoperative blood loss, number of units of transfusion products given, operating time, and inpatient length of stay of 74 patients with squamous cell carcinoma were compared. Patients who underwent classic tumour surgery were compared with a group treated with Harmonic Focus+ scissors. A significantly lower intraoperative blood loss (496.15?ml vs 1096.0?ml, respectively; P?=?0.002) and shorter operation time (436.89 minutes vs 493.13 minutes, respectively; P?=?0.030) were achieved using the Harmonic Focus+ scissors when compared to the classic tumour surgery. Additionally, fewer units of blood products needed to be transfused (administration of red cell concentrates, P?<?0.001) and the length of stay in the intensive care unit was shorter for patients treated with the Harmonic Focus+ scissors (P?=?0.009). The study results indicate that the use of Harmonic Focus+ scissors during surgery for cancer of the oral cavity and pharynx is a safe and cost-effective method. This is of paramount importance during a pandemic when medical resources are scarce, including access to blood reserves. 相似文献
6.
目的 对2019—2021年天津市人民医院贝伐珠单抗的临床应用情况进行评价,以期促进贝伐珠单抗超说明书用药的管理及其临床合理应用。方法 回顾性分析天津市人民医院2019年1月—2021年12月使用贝伐珠单抗患者的用药信息,根据说明书及指南评价其应用的合理性。结果 共收集1 313例患者(6 134次医嘱),通过适应症、治疗方案、用法用量3个方面评价应用合理性。结果 显示,存在适应症不适宜情况占比0.07%,用法用量不适宜情况占比4.77%,其中包括给药浓度不适宜(1.21%)、给药途径不适宜(0.23%)、与手术间隔时间不适宜(3.33%)。结论 天津市人民医院贝伐珠单抗的临床应用基本符合国内外说明书及指南要求,但也存在一定的超说明书用药情况。医院及临床药师应持续规范抗肿瘤药物超说明书使用的管理,促进抗肿瘤药物的合理应用。 相似文献
7.
目的 探讨丹青胶囊联合他扎罗汀倍他米松治疗银屑病的临床疗效.方法 选取2019年6月—2021年6月在天津市职业病防治院门诊皮肤科就诊治疗的114例银屑病患者,根据随机数字法分为对照组和治疗组,每组各57例.对照组患者给予他扎罗汀倍他米松乳膏,洗净患处,待皮肤干爽后,将适量本品均匀涂抹于患处,1次/d.治疗组患者在对照组治疗基础上口服丹青胶囊,4粒/次,3次/d.两组患者均连续治疗7 d.观察两组患者的临床疗效和临床症状好转时间,比较两组治疗前与治疗1、4、8周的皮损面积和严重程度指数(PASI)评分和血清炎性因子水平.结果 治疗后,治疗组总有效率是98.25%,显著高于对照组的82.46%(P<0.05).治疗后,治疗组患者皮损暗红、皮损肥厚、皮肤瘙痒、皮肤疼痛等症状好转时间均显著短于对照组(P<0.05).治疗后,两组PASI评分均较治疗前显著降低(P<0.05);治疗1、4、8周治疗组PASI评分显著低于对照组(P<0.05).治疗后,两组患者血清炎性因子白细胞介素6(IL-6)、白细胞介素17(IL-17)、肿瘤坏死因子α(TNF-α)、干扰素-γ(IFN-γ)水平均较治疗前显著降低(P<0.05);治疗后,治疗组血清炎性因子水平显著低于对照组(P<0.05).结论 丹青胶囊联合他扎罗汀倍他米松治疗银屑病效果明显,能显著降低炎性因子水平,并有助于改善皮损情况,值得临床推广应用. 相似文献
8.
Eulerian Algorithms for Computing the Forward Finite Time Lyapunov Exponent Without Finite Difference upon the Flow Map 下载免费PDF全文
Guoqiao You Changfeng Xue & Shaozhong Deng 《Communications In Computational Physics》2022,31(5):1467-1488
In this paper, effective Eulerian algorithms are introduced for the computation of the forward finite time Lyapunov exponent (FTLE) of smooth flow fields. The
advantages of the proposed algorithms mainly manifest in two aspects. First, previous
Eulerian approaches for computing the FTLE field are improved so that the Jacobian
of the flow map can be obtained by directly solving a corresponding system of partial
differential equations, rather than by implementing certain finite difference upon the
flow map, which can significantly improve the accuracy of the numerical solution especially near the FTLE ridges. Second, in the proposed algorithms, all computations
are done on the fly, that is, all required partial differential equations are solved forward in time, which is practically more natural. The new algorithms still maintain the
optimal computational complexity as well as the second order accuracy. Numerical
examples demonstrate the effectiveness of the proposed algorithms. 相似文献
9.
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献